Dr. Brian Lawenda

Dr. Brian Lawenda Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Dr. Brian Lawenda, Oncologist, 8026 S Tamiami Trail, Venice, FL.

Radiation Oncologist, Integrative Oncologist, Author, VeloNote Founder and CEO

Schedule a virtual consultation with me https://mitochondriamethod.com/consultations
VeloNote AI Medical Record Summarizer
https://velonote.com/ EXPERTISE:

--Radiation Oncology (Brain, Breast, Gastrointestinal, Gynecological, Head and Neck, Lung, Prostate/Genitourinary, Skin Cancers, Brachytherapy, Stereotactic Radi

osurgery/SRS, Stereotactic Body Radiation Therapy/SBRT, IMRT/VMAT)

--Functional Medicine

--Integrative Oncology

--Medical Acupuncture

--Medical Expert Witness

POSTGRADUATE EDUCATION:

--Functional Medicine: Functional Medicine Mentorship Program, Kalish Institute of Functional Medicine

--Medical Acupuncture: UCLA/Stanford Universities Schools of Medicine/Helms Medical Institute, Berkeley, CA

--Residency: Radiation Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (Chief Resident)

--Internship: General Surgery, Naval Medical Center San Diego, San Diego, CA

EDUCATION:

--Medical School: Temple University School of Medicine, Philadelphia, PA (Doctor of Medicine); Alpha Omega Alpha Honors Medical Society

--Undergraduate: University of California at San Diego, La Jolla, CA (Bachelor of Science in Biochemistry and Cellular Biology) and University of Kent, Canterbury, United Kingdom (Minors: British History and Art History)

WEBSITES:

--IntegrativeOncology-Essentials.com (Dr. Lawenda's integrative oncology and functional medicine educational blog)

---IOEprogram.com (Dr. Lawenda's integrative online integrative oncology and functional medicine patient course "IOE Online Program", Zoom and phone consultations and functional medicine lab testing)

TL;DRSleeping cooler does not treat cancer, prevent recurrence, or replace real oncology care. The direct evidence linki...
05/15/2026

TL;DR

Sleeping cooler does not treat cancer, prevent recurrence, or replace real oncology care. The direct evidence linking bedroom temperature itself to cancer outcomes is weak. But sleep quality, circadian rhythm, melatonin signaling, metabolism, inflammation, and immune regulation are all biologically relevant to cancer prevention and survivorship. A cooler bedroom may help some people sleep better and protect the normal nighttime physiology the body uses for repair. The key is not to sleep as cold as possible. The goal is a dark, comfortably cool, consistent sleep environment that supports circadian rhythm and restorative sleep.

Sleeping Cooler and Cancer: The Quiet Biology of a Better Night

At some point in the evening, often without noticing it, the body begins to prepare for the night. Core temperature starts to drift downward. Melatonin begins to rise. Cortisol should quiet. The nervous system is supposed to loosen its daytime grip. The brain, immune system, hormones, metabolism, and repair pathways begin shifting into a different mode.

Most of us think of sleep as a shutdown. It is not. Sleep is a highly active biological state. And the room we sleep in, including its temperature, may influence whether the body can enter that state cleanly.

The room is not the treatment. It is the signal. That distinction matters.

Sleeping in a cooler room does not treat cancer. It does not prevent recurrence, kill cancer cells, or replace surgery, radiation therapy, chemotherapy, immunotherapy, hormone therapy, targeted therapy, surveillance, or anything else in real oncology care. But it may support something that is deeply relevant to cancer biology: the integrity of the night.

The direct evidence linking bedroom temperature itself to cancer outcomes is weak. No one has proven that sleeping at 66 degrees instead of 72 degrees reduces cancer risk. The stronger science is about sleep quality, circadian rhythm, melatonin, metabolism, immune function, and inflammation. Those systems are all connected to cancer biology. Bedroom temperature is simply one modifiable part of that larger environment.

The body is designed to cool down as sleep approaches. That drop in core temperature helps signal the transition from daytime physiology to nighttime restoration. When the bedroom is too warm, many people sleep more lightly, wake more often, or spend the night in a more restless thermal state. The body is trying to dump heat when it should be sinking into deeper sleep.

But colder is not automatically better. The relationship between temperature and sleep is probably not linear. It is more likely U-shaped. Too warm can fragment sleep, but too cold can also make sleep worse, especially if someone is shivering, tense, waking up chilled, or piling on blankets.

Some people sleep poorly in cold rooms. Older adults, people with low body weight, hypothyroidism, poor circulation, chronic illness, or treatment-related fatigue may need a warmer environment to sleep well. In some people, warmth may even help sleep maintenance. So the goal is not to turn sleep into cold exposure therapy. The goal is to find the thermal environment that allows the body to fall asleep, stay asleep, and recover.

That point is especially important in cancer survivorship, where sleep is often already disrupted. Hot flashes, endocrine therapy, androgen deprivation therapy, corticosteroids, pain, neuropathy, anxiety, alcohol, late meals, and night sweats can all fragment sleep. In that setting, the bedroom environment is not trivial. It may be one of the few variables a patient can actually control.

The cancer connection begins with circadian rhythm. The International Agency for Research on Cancer has classified night-shift work involving circadian disruption as probably carcinogenic to humans. That does not mean a late bedtime or a warm bedroom causes cancer. It means chronic disruption of the internal clock is biologically important.

But even here, the evidence needs to be handled carefully. Some studies have found increased breast cancer risk in women with long histories of rotating night-shift work. Other large studies have not found the same association. So this is not a clean, simple story. It is a serious biologic concern with mixed epidemiologic data.

The reason the concern remains is that the internal clock is not just about feeling sleepy. Circadian rhythm helps regulate melatonin, cortisol, insulin sensitivity, immune surveillance, inflammation, DNA repair, cell-cycle signaling, and hormone metabolism. These are not fringe pathways. They are central features of the biological terrain in which cancer risk, progression, and recovery are studied.

The strongest circadian risk signals come from light at night, shift work, irregular sleep timing, and repeated misalignment between the body’s internal rhythm and the external world. Light is probably the dominant environmental signal here. Darkness at night and bright light in the morning matter more than whether the bedroom is set to a perfect temperature.

Bedroom temperature is a weaker and more indirect piece of the story. But it still belongs in the conversation because thermoregulation and circadian rhythm are linked. A cool, dark, consistent bedroom sends the body one signal. A bright, hot, fragmented night sends another.

Melatonin is part of that story. Most people know melatonin as the sleep hormone. That description is true, but incomplete. Melatonin is also involved in antioxidant defense, mitochondrial function, immune regulation, estrogen signaling, DNA repair, and cell-growth pathways. In laboratory studies, melatonin has shown anti-proliferative, pro-apoptotic, anti-angiogenic, and immunomodulatory effects across multiple cancer models.

That sounds more dramatic than the human evidence allows. Melatonin is not established as a cancer prevention strategy or cancer treatment. Most of the strongest cancer-related data are preclinical. Some clinical studies have suggested possible benefit when melatonin is used as an adjunct in cancer care, but the quality of evidence remains limited. This is not a place for overstatement.

Still, the biology is meaningful enough that protecting normal nighttime melatonin signaling is a reasonable goal. The most important step is darkness. Less bright light at night. Less blue-spectrum light before bed. More consistent sleep timing. Morning light exposure to anchor the clock.

Temperature is secondary. But secondary does not mean irrelevant. A comfortably cool bedroom may help support the normal nighttime physiology in which core temperature falls, melatonin rises, and sleep consolidates. The cooler room is not the medicine. It is part of the setting in which the body’s nighttime medicine is allowed to work.

There is also a metabolic angle, and it is one of the more interesting pieces of the story. A small human study found that men who slept for a month in a cooler room, around 66 degrees Fahrenheit, had increased brown fat activity and improved insulin sensitivity. Brown fat is metabolically active tissue that helps regulate heat and energy use. The finding was fascinating, but the study was tiny: only five men. It should not be used to claim that cooler sleep prevents cancer.

Still, the signal is intriguing because metabolic health matters in oncology. Insulin resistance, obesity, elevated glucose, chronic inflammation, and altered adipokine signaling are associated with higher risk of several cancers, including breast, colorectal, endometrial, liver, pancreatic, and others. Better metabolic health is not a fringe wellness goal. It is part of serious cancer prevention and survivorship medicine.

The chain of evidence remains indirect. Cooler sleep may help some people sleep better. Better sleep may support healthier metabolism. Healthier metabolism is relevant to cancer risk and recovery. That is not a cancer treatment claim. It is a biologically plausible connection, with several steps in between.

The same is true for immune function. The immune system does not go offline at night. Sleep helps regulate inflammatory signaling, T-cell function, natural killer cell activity, cytokine rhythms, and the stress response. Sleep deprivation can impair immune function, and animal studies suggest that chronic sleep disruption can worsen antitumor immune responses.

This does not prove that a cooler bedroom improves anticancer immunity. But a hot, restless, fragmented night is not the same biological environment as a cool, dark, consolidated night of sleep. One is more stressful. The other is more restorative. For someone trying to lower inflammation, recover from treatment, tolerate hormone therapy, rebuild resilience, or improve metabolic health, that difference may matter.

The practical question, then, is not whether sleeping cooler “fights cancer.” That is the wrong frame. The better question is whether the bedroom is helping or interfering with the biology of repair.

For many adults, a room somewhere in the 60s Fahrenheit is often recommended, and many people do well around the mid-60s. But there is no universal perfect number. The evidence is not strong enough to be dogmatic, and the ideal temperature varies by age, body composition, bedding, humidity, medical conditions, hormones, medications, and personal preference.

If you are sweating, restless, throwing off the covers, waking repeatedly, or feeling overheated, the room is probably too warm. If you are shivering, tense, waking up cold, or piling on blankets, it is probably too cold. The goal is not the coldest room. The goal is the best sleep.

For some people, that means lowering the thermostat. For others, it means lighter bedding, a fan, breathable sheets, moisture-wicking sleepwear, better humidity control, a cooling mattress pad, or avoiding alcohol and heavy meals late in the evening. For patients with hot flashes or night sweats, bedding may matter as much as the thermostat.

A cancer-conscious sleep environment does not need to be complicated. Make the room dark. Very dark. Light at night is one of the most important disruptors of melatonin and circadian rhythm. Keep the room cool enough that the body can naturally drop its core temperature, but not so cold that sleep becomes fragmented. Keep sleep timing as consistent as possible.

Avoid the usual nighttime saboteurs: alcohol, late heavy meals, late screens, overheating, and sleeping in a stuffy room. Get bright outdoor light in the morning. Morning light strengthens the circadian signal that makes nighttime biology work better.

None of this is dramatic. That is precisely why it is easy to dismiss. But cancer biology is shaped by repeated signals. One meal matters less than the pattern of eating. One workout matters less than the pattern of movement. One bad night of sleep matters less than the repeated rhythm the body lives in night after night.

The bedroom is part of that rhythm.

So no, sleeping cooler is not a cancer therapy. It has not been proven to prevent cancer or reduce recurrence. The temperature piece is indirect, and that matters.

But protecting sleep is not trivial. Protecting circadian rhythm is not trivial. Protecting the biology of the night is not trivial. For many people, a cooler, darker, more consistent bedroom is one of the simplest ways to begin.

Not because it is a cure. Because it is a signal the body understands.

And in health, as in cancer biology, the quiet daily signals often matter more than we think.

TLDR: BPC-157 has not been proven to cause cancer. But it has also not been proven safe in people with active cancer, re...
05/14/2026

TLDR: BPC-157 has not been proven to cause cancer. But it has also not been proven safe in people with active cancer, recent cancer, premalignant conditions, suspicious lesions, or high recurrence risk. The concern is not that BPC-157 clearly mutates DNA. The concern is that it may stimulate tissue-repair and blood-vessel-growth pathways that cancer can also use. That is enough for me to be cautious, especially in people with active cancer, recent cancer, premalignant disease, suspicious lesions, or high recurrence risk.

BPC-157 has become one of the most talked-about “healing peptides” in the wellness and performance world. It is promoted for tendon injuries, joint pain, gut repair, inflammation, surgical recovery, athletic recovery, and tissue regeneration.

The pitch sounds appealing. Damaged tissue needs help healing, and BPC-157 may support that process.

But when someone has cancer, a recent cancer history, a suspicious lesion, a rising tumor marker, or a meaningful recurrence risk, the question changes.

It is no longer just, “Can this help tissue heal?”

It becomes, “What exactly are we stimulating?”

That is the part of the BPC-157 conversation that deserves much more caution than it usually gets.

The concern is not that BPC-157 has been proven to cause cancer. It has not. The concern is that some of the same pathways that make BPC-157 interesting as a tissue-repair peptide are also pathways cancer can exploit.

This is not a “BPC-157 definitely causes cancer” argument. That would overstate the evidence. This is a “we should not casually use pro-repair, pro-angiogenic peptides in people with cancer risk and pretend the biology is irrelevant” argument.

And that is a much more defensible position.

The Key Issue: Angiogenesis

The most important cancer-related concern with BPC-157 is angiogenesis, which means new blood vessel formation.

In normal healing, angiogenesis can be helpful. Injured tissue needs oxygen, nutrients, immune cells, and repair signals. New blood vessels can help deliver those things.

But cancer also uses angiogenesis.

A microscopic tumor can only grow so far without a blood supply. At some point, if it wants to expand, it needs oxygen and nutrients. One of the classic hallmarks of cancer is the ability to stimulate or access new blood vessels.

That is why the VEGF pathway is such a major target in oncology.

VEGF stands for vascular endothelial growth factor. VEGF and its receptors, especially VEGFR2, are central regulators of blood vessel growth. This pathway is so important in cancer that multiple cancer drugs are designed to block VEGF-driven angiogenesis, including bevacizumab and several VEGFR-targeting tyrosine kinase inhibitors.

So when a peptide is shown to activate VEGFR2-related signaling, that is not a minor mechanistic detail. It is exactly the kind of finding that should make us pause.

A key preclinical study by Hsieh and colleagues found that BPC-157 increased vessel density in experimental models, upregulated VEGFR2 expression, promoted VEGFR2 internalization, and activated the VEGFR2-Akt-eNOS signaling pathway.

In plain English, BPC-157 appeared to activate a blood-vessel-growth pathway that is highly relevant to cancer biology.

That does not prove it promotes cancer. But it does explain why the concern is biologically plausible.

The same mechanism that may be helpful in ischemic tissue, injured tendon, or damaged gut may be undesirable near microscopic residual cancer.

This Is Not About “Causing Cancer” in the Usual Sense

When people hear “cancer risk,” they often think of something that directly damages DNA: cigarette smoke, radiation exposure, certain chemicals, or some viruses.

That is cancer initiation.

BPC-157 is not mainly concerning because we know it mutates DNA. In fact, formal preclinical toxicology testing in mice, rats, rabbits, and dogs reported no genetic toxicity, no embryo-fetal toxicity, and no serious organ-system toxicity. That is reassuring as far as it goes.

But it does not answer the question I care about most.

Could BPC-157 influence the behavior of cancer that is already there?

That is a different question.

A compound does not need to be a DNA-damaging carcinogen to influence cancer biology. Estrogen does not need to mutate DNA to affect estrogen-sensitive breast cancer. Testosterone does not need to be a mutagen to influence prostate biology. Growth factors, inflammatory signals, angiogenic pathways, and stromal remodeling can all affect cancer behavior without initiating cancer from scratch.

That is the more relevant concern here.

The question is not simply whether BPC-157 causes cancer. The better question is whether it could make an existing microscopic cancer deposit, dormant micrometastasis, premalignant lesion, or tumor microenvironment more favorable for growth.

And that question has not been answered.

Cancer Is an Ecosystem

One of the biggest mistakes in wellness medicine is treating cancer as if it is only a ball of malignant cells.

It is not.

Cancer is an ecosystem. Tumors interact with blood vessels, immune cells, fibroblasts, inflammatory signals, platelets, nerves, extracellular matrix, hormones, and metabolic conditions. The surrounding environment can either restrain cancer or help it progress.

This is why “regenerative” therapies deserve caution in people with cancer risk.

When someone says, “This helps tissue heal,” my next question is: which tissue, under what conditions, in what host, and with what hidden biology present?

A pro-repair signal in a damaged tendon may be useful. A pro-repair signal in a tumor bed after surgery may be more complicated. A pro-angiogenic signal in ischemic muscle may be helpful. A pro-angiogenic signal near microscopic residual disease may be concerning.

This is the problem with applying wellness logic to cancer biology.

Cancer is not simply “inflammation bad, repair good.”

Cancer often hijacks repair programs. Tumors can behave like wounds that do not heal properly. They recruit blood vessels, remodel tissue, manipulate immune signaling, activate stromal cells, and use normal healing pathways for abnormal growth.

So the fact that BPC-157 may support tissue repair is not automatically reassuring.

It is exactly why the oncology question deserves caution.

The Nuance: BPC-157 May Not Be a Simple Angiogenesis Switch

To be fair, the biology is not as simple as “BPC-157 equals angiogenesis equals cancer.”

Some preclinical work suggests BPC-157 may be more angiomodulatory than purely pro-angiogenic. In other words, it may influence angiogenesis differently depending on tissue context, injury state, nitric oxide balance, and local physiology.

That nuance matters.

A peptide that drives angiogenesis everywhere, regardless of context, would raise a much stronger cancer concern. A peptide that mainly helps restore blood flow in injured or ischemic tissue, without independently causing pathologic neovascularization, would be a different risk profile.

Some investigators, particularly the Sikiric group, have argued that BPC-157 controls or modulates angiogenesis rather than simply promoting it. They have also argued that it may oppose certain forms of pathological angiogenesis and may have anti-tumor potential in some experimental settings.

That should not be ignored.

But it should not be overinterpreted.

There is a major difference between saying BPC-157 may have complex biology, including possible anti-tumor effects in selected experimental contexts, and saying BPC-157 is safe for people with cancer or cancer risk.

Those are not the same claim.

The anti-tumor claims appear to come largely from the same research network, and the specific tumor model data are not yet detailed enough, replicated enough, or clinically mature enough to settle the question that matters most.

What happens when BPC-157 is given to animals with established tumors, dormant micrometastases, premalignant lesions, or residual disease after cancer therapy?

Does tumor growth increase, decrease, or remain unchanged? Does tumor vascular density change? Does metastatic burden change? Does recurrence risk change? Does survival change? Does the answer differ by cancer type, dose, route, timing, or duration?

Until those studies are done rigorously, “possible anti-tumor activity” should be treated as hypothesis-generating, not reassuring.

The Human Evidence Is Thin

For all the excitement around BPC-157, the human evidence is remarkably limited.

A 2025 systematic review in orthopedic sports medicine identified hundreds of BPC-157-related articles but found only one human clinical study, a retrospective case series of 12 patients with knee pain. That is not enough to establish meaningful human safety.

A 2025 literature and patent review also noted that BPC-157 has not been approved by the FDA or other major regulatory authorities because of insufficient clinical studies. A 2026 narrative review in sports medicine similarly emphasized that rigorous human safety data remain scarce and that unapproved peptide therapies may carry potential for serious harm.

So when someone says, “There is no evidence BPC-157 causes cancer,” that is technically true.

But it is incomplete.

There is also no adequate human evidence proving it is safe in cancer survivors, people with premalignant conditions, people with occult malignancy, or people with active cancer.

The Missing Study Is the Study We Actually Need

The problem with BPC-157 is not that we have strong evidence showing it promotes cancer.

We do not.

The problem is that we do not have the right evidence showing it does not.

The studies we need are obvious. Does BPC-157 accelerate growth of established tumors? Does it increase tumor blood-vessel density? Does it increase metastatic burden? Does it stimulate dormant micrometastases? Does it change recurrence after surgery, radiation, chemotherapy, targeted therapy, or immunotherapy?

Does the effect differ in breast cancer, prostate cancer, melanoma, colon cancer, glioblastoma, lymphoma, pancreatic cancer, or sarcoma? Does dose matter? Does route matter? Does duration matter? Does timing matter? Does it behave differently during active inflammation, wound healing, post-operative recovery, radiation therapy, or immunotherapy?

Those are not academic questions. Those are the questions that determine whether this is reasonable or reckless in cancer patients.

Right now, the honest answer is that we do not know enough.

And when the mechanism overlaps with pathways cancer can use, “we do not know” is not the same as “go ahead.”

The Real-World Problem

Even if the biology were less concerning, the real-world market would still be a problem.

Many people are not getting BPC-157 as part of a carefully monitored clinical trial. They are getting it from wellness clinics, med spas, online peptide sellers, overseas suppliers, or “research chemical” vendors.

That creates practical risks that are separate from the molecule itself: purity, sterility, dose accuracy, peptide degradation, contamination, batch variability, route of administration, duration of use, stacking with other peptides, and use in people who may have undiagnosed cancer.

The FDA has specifically raised concerns about compounded BPC-157, including immunogenicity, peptide-related impurities, and inadequate safety information for proposed human routes of administration. Those concerns are not just bureaucratic. Peptides can be difficult to characterize, and small differences in sourcing, formulation, dose, and administration can matter.

Online, people often discuss BPC-157 as though everyone is using the same pharmaceutical-grade substance at the same dose, by the same route, with the same supervision.

That is not reality.

How I Would Think About It Clinically

For a healthy person with no cancer history using BPC-157 briefly for a tendon injury, the cancer risk is unknown. I would not say it is proven dangerous. I would say the claims are ahead of the human safety data, and quality-control concerns are real.

For someone with active cancer, recent cancer, suspicious imaging, rising tumor markers, known residual disease, or high recurrence risk, I would generally avoid it.

I would be especially cautious in people on active surveillance for prostate cancer, MGUS, smoldering myeloma, Barrett’s esophagus with dysplasia, high-risk colon polyps, pancreatic cysts, cirrhosis, or a suspicious lung nodule.

For someone receiving radiation therapy, chemotherapy, immunotherapy, targeted therapy, or recovering from cancer surgery, I would not add BPC-157 casually.

Not because we know it is harmful.

Because we do not know it is safe.

And the biology gives us a reason to pause.

My Bottom Line

BPC-157 has not been proven to cause cancer in humans. It has not been proven to increase recurrence risk in cancer survivors. It has not been proven to accelerate metastases.

There are preclinical toxicology data showing no obvious genotoxicity or serious organ toxicity in standard animal models. There are also research groups arguing that BPC-157 may regulate angiogenesis rather than simply stimulate it, and that it may have anti-tumor potential in certain experimental settings.

But none of that answers the most important clinical question.

Is BPC-157 safe in people with active cancer, recent cancer, premalignant conditions, suspicious lesions, dormant micrometastatic disease, or high recurrence risk?

We do not know.

The precautionary concern remains legitimate because BPC-157 interacts with angiogenesis, VEGFR2-Akt-eNOS signaling, nitric oxide biology, tissue repair, and remodeling pathways that are directly relevant to cancer behavior.

For people without cancer, the risk is unknown.

For people with active cancer, recent cancer, suspicious lesions, premalignant disease, or high recurrence concern, I would generally avoid BPC-157 unless there is a compelling medical reason and the oncology team is involved.

In medicine, “not proven dangerous” is not the same as “proven safe.”

And when the mechanism overlaps with a hallmark of cancer, that difference matters.

A new breast cancer study just came out in JAMA Network Open, and one number is going to get a lot of attention.https://...
05/13/2026

A new breast cancer study just came out in JAMA Network Open, and one number is going to get a lot of attention.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848788

Women with breast cancer and type 2 diabetes who used GLP-1 drugs had a reported 91% lower relative hazard of death compared with women treated with insulin or metformin.

That is a massive number.

These are the drugs most people know as Ozempic, Wegovy, Mounjaro, and Zepbound.

So the obvious question is: are these drugs somehow protecting women after breast cancer?

Maybe.

But this is where we need to be very careful.

This study does not prove that Ozempic or Mounjaro prevents breast cancer recurrence. It does not prove these drugs directly fight breast cancer. And it does not show that fewer women died specifically from breast cancer.

The endpoint was all-cause mortality, meaning death from any cause. That could include breast cancer, but it could also include heart disease, stroke, infection, or anything else. 

The recurrence endpoint also needs a little caution. Recurrence-free survival in this study was based on medical codes for metastatic or distant recurrence. That is not the same thing as an oncologist reviewing every scan, biopsy, pathology report, and clinical note to confirm each recurrence. 

So no, this is not proof.

But I would not dismiss it either.

The researchers used a large electronic health record database and started with more than 841,000 women with breast cancer. They focused on women with stage I to III breast cancer who also had obesity or type 2 diabetes. Patients with stage IV disease or known metastatic disease were excluded. 

In the diabetes group, the numbers looked striking.

Deaths occurred in 0.8% of GLP-1 users compared with 7.7% of patients treated with insulin or metformin. That is where the 91% relative reduction comes from. 

The recurrence numbers also favored the GLP-1 group. Coded metastatic recurrences occurred in 1.4% of GLP-1 users compared with 3.9% of insulin or metformin users. 

Among women with obesity and breast cancer, GLP-1 users also did better than nonusers. Deaths occurred in 1.2% versus 3.7%, and coded recurrences occurred in 2.6% versus 5.8%. 

Those are interesting numbers.

But here is the part that keeps me from overreacting.

The results looked much less dramatic when GLP-1 drugs were compared with SGLT2 inhibitors, another newer class of diabetes drugs that also has major heart and metabolic benefits.

In that comparison, deaths were almost identical: 7.0% with GLP-1 drugs and 7.1% with SGLT2 inhibitors. Coded recurrences were also very similar: 3.1% versus 3.3%. 

That matters.

If GLP-1 drugs had a strong, unique anticancer effect, you might expect them to clearly outperform another modern diabetes drug class. They really did not, at least in the unadjusted analysis.

That does not mean GLP-1 drugs are irrelevant. It may mean the real story is broader than GLP-1 itself.

Maybe this is about metabolic health.

Maybe it is about weight loss.

Maybe it is about insulin resistance.

Maybe it is about inflammation.

Maybe it is about cardiovascular risk.

Maybe it is about the fact that patients getting newer metabolic drugs are different from patients on older diabetes regimens. They may have better access to care, more physician follow-up, better insurance coverage, or more aggressive risk-factor management.

That is the problem with retrospective database studies. They can show signals. They can generate hypotheses. But they cannot prove causation.

There are also some breast cancer-specific issues. Breast cancer is not one disease. ER status matters. HER2 status matters. Tumor grade, lymph nodes, genomic risk, endocrine therapy adherence, surgery, radiation, chemotherapy, and systemic therapy all matter.

Large electronic health record studies often do not capture those details cleanly. The authors acknowledge that the cancer details were incomplete. They also did not have patient-level weight loss data, so we do not know whether the apparent benefit was related to actual weight loss, better blood sugar, lower insulin levels, improved inflammation, cardiovascular benefit, or something else. 

So where do I land?

I would not call GLP-1 drugs breast cancer drugs.

Not yet.

I would not tell breast cancer survivors to start Ozempic or Mounjaro because of this study.

But I also would not ignore the signal.

The bigger message may be that the body’s metabolic environment matters after breast cancer.

Obesity is not just extra weight. It is often tied to insulin resistance, chronic inflammation, hormonal changes, immune dysfunction, and metabolic stress. Type 2 diabetes brings its own problems: high insulin, high glucose, vascular disease, inflammation, and higher cardiovascular risk.

All of that can influence long-term health. And it may influence cancer outcomes too.

For patients, my takeaway is pretty simple: if you have had breast cancer and also have obesity, prediabetes, insulin resistance, or type 2 diabetes, this is worth discussing with your oncology team, primary care doctor, or endocrinologist.

Not because GLP-1 drugs are proven to prevent recurrence.

They are not.

But because metabolic health should not be treated as an afterthought in breast cancer survivorship.

The tumor matters. The treatment matters. Surgery, radiation, chemotherapy, endocrine therapy, HER2-directed therapy, immunotherapy, CDK4/6 inhibitors, and appropriate surveillance still matter enormously.

But the terrain matters too.

This study does not prove that Ozempic or Mounjaro prevents breast cancer recurrence.

What it does suggest is that the metabolic health conversation in breast cancer survivorship may need to get a lot more serious.

Address

8026 S Tamiami Trail
Venice, FL
34293

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

(941)2206460

Alerts

Be the first to know and let us send you an email when Dr. Brian Lawenda posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Category